Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy

Javier Vaquero, Robert J. Fontana, Anne M. Larson, Nathan M.T. Bass, Timothy J. Davern, A. Obaid Shakil, Steven Han, M. Edwyn Harrison, Todd R. Stravitz, Santiago Muñoz, Robert Brown, William M. Lee, Andres T. Blei – 28 November 2005 – Monitoring of intracranial pressure (ICP) in acute liver failure (ALF) is controversial as a result of the reported complication risk (∼20%) and limited therapeutic options for intracranial hypertension.

Chicken pox after pediatric liver transplantation

Josh Levitsky, Andre C. Kalil, Jane L. Meza, Glenn E. Hurst, Alison Freifeld – 28 November 2005 – Previous case series have reported serious complications of chicken pox (CP) after pediatric liver transplantation (PLT), mainly due to visceral dissemination. The goal of our study was to determine the incidence, risk factors, and outcomes of CP after PLT. A case‐control study of all CP infections in pediatric transplant recipients followed at our center from September 1993 to April 2004 was performed.

Activation pattern of mitogen‐activated protein kinases in early phase of different size liver isografts in rats

Tingbo Liang, Shiguo Xu, Jun Yu, Kezhen Shen, Donglin Li, Shusen Zheng – 28 November 2005 – Mitogen‐activated protein kinases (MAPK) play a pivotal role in ischemia reperfusion injuries of heart and liver, but the activation pattern of MAPKs in the early phase of different size liver isografts remains unclear. The experiment is designed to investigate the activation pattern and role of MAPKs in isografts of the rat with different size liver transplantation.

Recurrent hepatitis C after retransplantation: Factors affecting graft and patient outcome

Michal Carmiel‐Haggai, M. Isabel Fiel, Himabindu C. Gaddipati, Chaim Abittan, Sabera Hossain, Sasan Roayaie, Myron E. Schwartz, Gabriel Gondolesi, Sukru Emre, Thomas D. Schiano – 28 November 2005 – Retransplantation (re‐LT) of patients with recurrent hepatitis C virus (HCV) carries significant morbidity and mortality, negatively impacting on an already scarce donor allograft pool. In this study, we investigated the outcome of allografts and patients after re‐LT due to recurrent HCV. Between 1989 and 2002, 47 patients were retransplanted at our institution due to HCV‐related graft failure.

Herpes simplex virus‐associated acute liver failure: A difficult diagnosis with a poor prognosis

Philippe Ichai, Anne Marie Roque Afonso, Mylène Sebagh, Maria Eugenia Gonzalez, Liana Codés, Daniel Azoulay, Faouzi Saliba, Vincent Karam, Elisabeth Dussaix, Catherine Guettier, Denis Castaing, Didier Samuel – 28 November 2005 – We report 5 cases of acute liver failure related to herpes simplex (HSV) infection in 1 immunocompetent and 4 immunosuppressed patients. One patient was too ill for liver transplantation indication. Three patients, among the 4 listed, underwent liver transplantation.

Recurrent hepatic sarcoidosis post‐liver transplantation manifesting with severe hypercalcemia: A case report and review of the literature

Cem Cengiz, Manuel Rodriguez‐Davalos, Graciela deBoccardo, M. Isabel Fiel, Gonzalo Rodriguez‐Laiz, Mark Kovacevic, Sukru Emre, Thomas Schiano – 28 November 2005 – Sarcoidosis is a systemic granulomatous disease primarily involving the lungs, lymph nodes, skin, eyes and nervous system; liver involvement is asymptomatic in most cases. However, once the patient develops clinical symptoms liver disease is usually progressive and may necessitate orthotopic liver transplantation. There are a few reports of asymptomatic recurrent sarcoidosis developing within the liver allograft.

Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation

Michelle Slifkin, Robin Ruthazer, Richard Freeman, Judy Bloom, Susan Fitzmaurice, Ralph Fairchild, Michael Angelis, Jeffrey Cooper, Laurie Barefoot, Richard Rohrer, David R. Snydman – 28 November 2005 – With improved cytomegalovirus (CMV) prophylaxis, CMV disease after liver transplantation has decreased dramatically, and patient and graft survival have improved. We examined the impact of CMV prophylaxis on biopsy proven rejection after orthotopic liver transplantation by analyzing data on 192 liver recipients over 5 years (1994‐1999).

Subscribe to